Bit.bio

bit.bio is a Cambridge, UK synthetic biology company founded in 2016 by stem cell biologist and neurosurgeon Mark Kotter, headquartered at the Babraham Research Campus with a second site in San Francisco and a discovery subsidiary (bit.bio discovery GmbH) in Vienna. Its proprietary opti-ox cell coding technology uses a dual genomic safe harbour approach to deterministically reprogram human induced pluripotent stem cells (iPSCs) into defined, consistent human cell types at industrial scale. The company sells these as ioCells — ioWild Type Cells, ioDisease Model Cells and CRISPR-Ready ioCells covering neurons, microglia, hepatocytes, glial and muscle lineages — plus custom iPSC-derived cell development and expert-led CRISPR functional genomics screening services for research, drug discovery and cell therapy. Products are sold as physical cell vials through a web storefront and a distributor network; bit.bio publishes no developer program, public API, or machine-readable API contract.

Bit.bio is profiled on the APIs.io network. Tagged areas include Company, Synthetic Biology, Biotechnology, Life Sciences, and Stem Cells.

Bit.bio’s developer surface includes support, engineering blog, product news, and 13 more developer resources.

🌐 Visit website 📡 Source on GitHub

13.7/100 emerging ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0

0 APIs

CompanySynthetic BiologyBiotechnologyLife SciencesStem CellsCell TherapyDrug DiscoveryGenomicsCRISPRResearch Reagents

Kin Score

Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0

Composite quality — 13.7/100 · emerging

Contract Quality 0.0 / 21

Developer Ergonomics 1.1 / 17

Commercial Clarity 3.6 / 17

Operational Transparency 0.6 / 11

Governance 0.0 / 10

Discoverability 5.8 / 9

Regulatory Posture 2.6 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/bit.bio: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Build 1

SDKs, sample code, and the tooling you integrate with

GitHubOrganization

GitHubOrganization

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 3

Status, limits, changes, and where to get help

Support

Support

HelpCenter

HelpCenter

ContactUs

ContactUs

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

TermsOfService

TermsOfService

Company 5

The organization behind the API

Website

Website

Blog

Blog

News

News

LinkedIn

Twitter

Twitter

Other 3

Properties that don't map to a standard resource type

Products

Products

Platform

Platform

SecondaryMarket

SecondaryMarket

Source (apis.yml)

aid: bit.bio
name: Bit.bio
description: bit.bio is a Cambridge, UK synthetic biology company founded in 2016 by stem cell biologist and neurosurgeon
  Mark Kotter, headquartered at the Babraham Research Campus with a second site in San Francisco and a discovery subsidiary
  (bit.bio discovery GmbH) in Vienna. Its proprietary opti-ox cell coding technology uses a dual genomic safe harbour approach
  to deterministically reprogram human induced pluripotent stem cells (iPSCs) into defined, consistent human cell types at
  industrial scale. The company sells these as ioCells — ioWild Type Cells, ioDisease Model Cells and CRISPR-Ready ioCells
  covering neurons, microglia, hepatocytes, glial and muscle lineages — plus custom iPSC-derived cell development and expert-led
  CRISPR functional genomics screening services for research, drug discovery and cell therapy. Products are sold as physical
  cell vials through a web storefront and a distributor network; bit.bio publishes no developer program, public API, or machine-readable
  API contract.
url: https://raw.githubusercontent.com/api-evangelist/bit.bio/refs/heads/main/apis.yml
image: https://14527135.fs1.hubspotusercontent-na1.net/hubfs/14527135/Logos/bit.bio/bitbio-logotype-no_tagline-color-positive-RGB.png
x-type: company
x-source: harvest:secondary-market
specificationVersion: '0.20'
created: '2026-08-07'
modified: '2026-08-07'
tags:
- Company
- Synthetic Biology
- Biotechnology
- Life Sciences
- Stem Cells
- Cell Therapy
- Drug Discovery
- Genomics
- CRISPR
- Research Reagents
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/bit.bio-domain-security.yml
- type: LLMsTxt
  url: llms/bit.bio-llms.txt
- type: Website
  url: https://www.bit.bio/
- type: Products
  url: https://www.bit.bio/products
- type: Platform
  url: https://www.bit.bio/platform
- type: Support
  url: https://www.bit.bio/support/technical-support
- type: HelpCenter
  url: https://www.bit.bio/support/technical-faqs
- type: Blog
  url: https://www.bit.bio/blog
- type: News
  url: https://www.bit.bio/news
- type: ContactUs
  url: https://www.bit.bio/contact-us
- type: GitHubOrganization
  url: https://github.com/Bit-Bio
- type: PrivacyPolicy
  url: https://www.bit.bio/privacy
- type: TermsOfService
  url: https://www.bit.bio/hubfs/Documents/Standard-Terms-and-Conditions-for-Sale-of-Goods-and-Services_v04.pdf
- type: LinkedIn
  url: https://www.linkedin.com/company/bitbioltd/
- type: Twitter
  url: https://x.com/bitbio
- type: SecondaryMarket
  url: https://www.hiive.com/securities/bit.bio-stock
x-enrichment:
  date: '2026-08-07'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: bit.bio sells cryopreserved human iPSC-derived cell vials and CRISPR screening services, ordered through a HubSpot
    marketing site and a Shopify storefront; there is no developer subdomain, no spec at any host root, and the only machine-readable
    endpoints on shop.bit.bio are Shopify platform defaults that an unrelated Shopify store returns identically.
  evidence:
  - url: https://www.bit.bio/openapi.json
    status: 404
  - url: https://www.bit.bio/.well-known/api-catalog
    status: 404
  - url: https://www.bit.bio/.well-known/agent-card.json
    status: 404
  - url: https://www.bit.bio/llms.txt
    status: 404
  - url: https://bitbiodiscovery.com/openapi.json
    status: 404
  - url: https://shop.bit.bio/.well-known/openid-configuration
    status: 200
  - url: https://www.allbirds.com/.well-known/openid-configuration
    status: 200
  checked: '2026-08-07'